Casolino Raffaella, Tatah Lambed, Charnaud Sarah, Santero Marilina, Ilbawi Andrè, Ross Anna Laura
Department of Noncommunicable Diseases, World Health Organization, Geneva, Switzerland.
Emerging Technology, Research Prioritization and Support Unit, Department of Research for Health, World Health Organization, Geneva, Switzerland.
Nat Med. 2025 Sep 9. doi: 10.1038/s41591-025-03926-x.
Clinical trials are essential to advancing cancer control, yet access and participation remain unequal globally. The World Health Organization (WHO) established the International Clinical Trials Registry Platform (ICTRP) to enable a complete view of interventional clinical research for all those involved in healthcare decision-making and to identify actionable goals to equitable participation at the global level. A review of 89,069 global cancer clinical trials registered in the WHO ICTRP between 1999 and December 2022 revealed a cancer clinical trial landscape dominated by high-income countries and focused on pharmacological interventions, with multinational collaboration limited to only 3% of recruiting trials. Several of the deadliest cancers, including liver, stomach, pancreas and cervical cancer, were consistently missing from the top most-studied cancer types, particularly in Africa and Southeast Asia. In this Review, we summarize the key findings of the WHO global landscape review and discuss strategies to act on these data, which provide critical empirical evidence to inform policy, practice and investment decisions.
临床试验对于推进癌症防治至关重要,但在全球范围内,获取试验机会和参与度仍然不平等。世界卫生组织(WHO)设立了国际临床试验注册平台(ICTRP),以便让所有参与医疗保健决策的人员全面了解干预性临床研究情况,并确定在全球层面实现公平参与的可行目标。对1999年至2022年12月期间在世卫组织ICTRP上注册的89,069项全球癌症临床试验进行的一项审查显示,癌症临床试验格局以高收入国家为主导,且侧重于药物干预,跨国合作仅占招募试验的3%。包括肝癌、胃癌、胰腺癌和宫颈癌在内的几种最致命癌症,一直未出现在研究最多的癌症类型前列,在非洲和东南亚尤其如此。在本综述中,我们总结了世卫组织全球格局审查的主要发现,并讨论根据这些数据采取行动的策略,这些数据提供了关键的实证依据,为政策、实践和投资决策提供参考。